

CONVERSION OF OA-6129 B₂ INTO
(5*R*,6*R*)-6-[(*R*)-1-FLUOROETHYL]-7-
OXO-3-[(*N,N,N'*-TRIMETHYL-
CARBAMIMIDOYL)METHYL]THIO-
1-AZABICYCLO[3.2.0]HEPT-2-ENE-
2-CARBOXYLIC ACID (88617)[†]

TAKEO YOSHIOKA, AZUMA WATANABE,
NORITAKA CHIDA and YASUO FUKAGAWA

Central Research Laboratories,
Sanraku Incorporated,
4-9-1 Johnan, Fujisawa 251, Japan

(Received for publication May 25, 1989)

Since the epoch-making discovery of thienamycin²⁾, a number of extensive studies have been carried out on the development of clinically useful carbapenem compounds. As a result, formimidoylthienamycin (imipenem) has recently been put on the market as a combination drug (Primaxin)³⁾ with cilastatin, a renal dehydropeptidase-I inhibitor⁴⁾. It has, however, a shortcoming in that its poor solubility in water⁵⁾, limits its clinical use to infusion.

MAK and FLIRI have succeeded in the total synthesis of novel 8-fluorinated carbapenem derivatives as racemates¹⁾ via the Melillo lactone⁶⁾. Among them, 88617 is most promising by virtue of excellent antimicrobial activity, improved resistance to dehydropeptidase-I and high physico-chemical stability. Subsequent biological evaluation studies, however, indicated that the optical activity of 8-fluoro carbapenem derivatives was critically important for expression of the desirable antimicrobial and enzymological profiles⁷⁾.

In the meanwhile, a series of OA-6129 carbapenems which are characterized by the C-3 pantetheinyl side chain are produced by a streptomycete⁸⁾; and a selective fermentation method of OA-6129 B₂ which has a 1-hydroxyethyl side chain at C-6 became available by mutagenesis of specifically-blocked strains⁹⁾. As the absolute configuration of the hydroxyl group is *S* in the C-6 side chain of OA-6129 B₂, it was thought that optically active 88617 could be prepared efficiently from OA-6129 B₂ by an *S*-oxide replacement reaction¹⁰⁾, if fluorination at C-8 proceeded under perfect inversion.

This paper describes the efficient conversion of

OA-6129 B₂, a fermentation carbapenem product, into optically active 88617, an 8-fluorinated carbapenem derivative which improved antimicrobial activity and dehydropeptidase-I stability.

Treatment of OA-6129 B₂ sodium salt **1** with *p*-nitrobenzyl (*p*NB) bromide or pivaloyloxymethyl chloride in DMF gave *p*NB ester **2** or pivaloyloxymethyl (POM) ester **3** of OA-6129 B₂ (Fig. 1). The two hydroxyl groups in the pantoyl moiety of OA-6129 B₂ were protected by isopropylideneation for differentiation from the C-8 hydroxyl group.


The protected compound **4** or **5** was allowed to react with 1.2 equiv of diethylaminosulfur trifluoride (DAST)¹¹⁾ at -68°C in methylene chloride for 10 minutes. After the reaction mixture was diluted with methylene chloride and washed with a saturated aqueous sodium bicarbonate solution, silica gel column chromatography of the organic layer provided the desired fluorinated compound **6** or **7** having a fluorine atom in the *R* configuration at C-8 in 43 or 49% yield, respectively. No epimer at C-8 was observed at all in these reaction conditions.

On the other hand, Ishikawa reagent (a mixture of diethylaminohexafluoropropane and diethylaminopentafluoropropane)^{††} with which it has been confirmed that fluorination proceeds by perfect inversion in the case of non-fused azetidiones (WATANABE, A. *et al.*; unpublished results), was also tested for stereospecific fluorination. However, treatment of **4** with 1.0 mol equiv of Ishikawa reagent afforded fluorinated compounds in 30% yield as a 1:1 mixture of the 8*R* and 8*S* epimers; (coupling constants $J_{6,8} = 7.3$ Hz, $J_{8,F} = 48.5$ Hz, $J_{8,9} = 6.4$ Hz for 8*R*, $J_{6,8} = 6.5$ Hz, $J_{8,F} = 46.2$ Hz, $J_{8,9} = 6.5$ Hz, for 8*S*); the ethylidene compound at C-6 was also produced in 10% yield. From these findings, it is concluded that DAST is better than Ishikawa reagent for the stereospecific fluorination of 8-hydroxycarbapenem compounds.

The fluorinated derivative **6** or **7** was oxidized with *m*-chloroperbenzoic acid in methylene chloride at -20~0°C to give the corresponding *S*-oxide **8** or **9** in 76 or 73% yield. **8** or **9** was treated with α -mercapto-*N,N,N'*-trimethylacetoamidine nonafluorobutanesulfonate or its hydrochloride, providing the *p*NB ester nonafluorobutanesulfonate **10** in 40% yield or the POM ester hydrochloride **11** in 56% yield after CM-Sephadex C-25 column chromatography. The physico-chemical properties of the

[†] See ref 1.

^{††} Ishikawa reagent was purchased from Tokyo Kasei Kogyo Co., Ltd.

Fig. 1. Conversion of OA-6129 B₂ into 88617.

sulfonate **10**: MP 140~142.5°C; $[\alpha]_D^{23} + 25.3^\circ$ (*c* 0.975, CH₂Cl₂); UV $\lambda_{\max}^{\text{CH}_2\text{Cl}_2}$ nm (ϵ) 269.5 (14,000), 312.5 (14,600); IR ν_{\max}^{KBr} cm⁻¹ 1775 (β -lactam); ¹H NMR (CDCl₃ + a few drops of DMSO-*d*₆) δ 1.43 (3H, dd, *J*=6.3 and 24.0 Hz, 9-H), 3.19 (3H, s, NCH₃ or =NCH₃), 3.30 (6H, s, =NCH₃ and NCH₃ or N(CH₃)₂), 3.3~3.8 (3H, m, 4-H and 6-H), 4.18 (2H, s, SCH₂), 4.33 (1H, m, 5-H), 4.6~5.4 (1H, m, 8-H); 5.20 (1H, d, *J*=14.1 Hz, CHH-Ar), 5.47 (1H, d, *J*=14.1 Hz, CHH-Ar), 7.62 (2H, d, *J*=9.0 Hz, Ar), 8.17 (2H, d, *J*=9.0 Hz, Ar), 8.3~8.9 (1H, br, SO₃H) were in good accordance with those of the authentic sample[†] synthesized by resolution of the Melillo lactone. Compound **10** was hydrogenated over 10% Pd-C in a mixture of ethyl acetate and 0.15 M MOPS buffer, pH 7.5, and purified by column chromatography on QAE-Sephadex A-25 and Diaion CHP-20 P to give 88617 in 43% yield as colorless crystals from ethanol.

Using a similar procedure, 8-fluorinated carbapenem derivatives having a variety of C-3 side chains were prepared. Their structure-activity relationships will be discussed in a separate paper.

Acknowledgment

We are indebted to Prof. Y. YAMADA, Tokyo College of Pharmacy, for his helpful advice and discussions on this work.

References

- 1) MAK, C. P. & H. FLIRI (SANDOZ): Fluoroalkylated carbapenem Derivatives. U.S. 4,720,490, Jan. 19, 1988
- 2) KAHAN, J.S.; F. M. KAHAN, R. GOEGELMAN, S. A. CURRIE, M. JACKSON, E. O. STAPLEY, T. W. MILLER, A. K. MILLER, D. HENDLIN, S. MOCHALES, S. HERNANDEZ, H. B. WOODRUFF & J. BIRNBAUM: Thienamycin, a new β -lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. *J. Antibiotics* 32: 1~12, 1979
- 3) Imipenem-Sodium Cilastatin (Primaxin). *Medical Lett. (Japanese)* 2: 29~31, 1986
- 4) GRAHAM, D. W.; W. T. ASHTON, L. BRASH, J. E. BROWN, R. D. BROWN, L. F. CANNING, A. CHEN, J. P. SPRINGER & E. F. ROGERS: Inhibition of the mammalian β -lactamase renal dipeptidase (dehydropeptidase-I) by (Z)-2-(acylamino)-3-substituted-propenoic acids. *J. Med. Chem.* 30: 1074~1090, 1987
- 5) SHIH, D. H.; F. BAKER, L. CAMA & B. G. CHRISTENSEN: Synthetic carbapenem antibiotics I. 1- β -Methylcarbapenem. *Heterocycles* 21: 29~40, 1984
- 6) MELILLO, D. G.; I. SHINKAI, T. LIU, K. RYAN & M. SLETZINGER: A practical synthesis of (\pm)-thienamycin. *Tetrahedron Lett.* 21: 2783~2786, 1980
- 7) WATANABE, A.; M. SAKAMOTO, Y. FUKAGAWA & T. YOSHIOKA: Syntheses and biological activities of new 8-fluorocarbapenem derivatives. *Chem. Pharm. Bull.*, in preparation
- 8) YOSHIOKA, T.; I. KOJIMA, K. ISSHIKI, A. WATANABE, Y. SHIMAUCHI, M. OKABE, Y. FUKAGAWA & T. ISHIKURA: Structures of OA-6129A, B₁, B₂ and C, new carbapenem antibiotics produced by *Streptomyces* sp. OA-6129. *J. Antibiotics* 36: 1473~1482, 1983
- 9) KOJIMA, I.; Y. FUKAGAWA, M. OKABE, T. ISHIKURA & N. SHIBAMOTO: Mutagenesis of OA-6129 carbapenem-producing blocked mutants and the biosynthesis of carbapenems. *J. Antibiotics* 41: 899~907, 1988
- 10) YAMAMOTO, K.; T. YOSHIOKA, Y. KATO, K. ISSHIKI, M. NISHINO, F. NAKAMURA, Y. SHIMAUCHI & T. ISHIKURA: Chemical modification of carbapenem antibiotics. Versatile methods for displacement of the C-3 sulfur side chain of carbapenems with other thiol groups. *J. Antibiotics* 36: 407~415, 1983
- 11) MAK, C. P. & K. WAGNER: Synthesis of fluorinated carbapenems. Reaction of monocyclic and bicyclic β -lactams with diethylaminosulfur trifluoride. *In* Recent Advances in the Chemistry of β -Lactam Antibiotics. Third International Symposium 1984. *Eds.*, A. G. BROWN & S. M. ROBERTS, pp. 366~370, The Royal Society of Chemistry, 1984

[†] The authentic sample of **10** was kindly supplied by Sandoz Company.